Myrian XL-Onco was developed and validated jointly with leading French experts
The unique solution for multi modality oncology follow-up, Myrian XL-Onco is the culmination of eight years of development of the Myrian platform.
Dedicated to oncology follow-up, it manages the sequencing of tasks essential for the management of the cancer patients with elevated efficiency and in strict compliance with the international RECIST rules, consensually established by European, Canadian and American authorities.
The Cheson protocol whose parameters can be set by the user is also available.
Myrian XL-Onco was developed and validated jointly with leading French experts. It makes Intrasense a world leader in oncology follow-up software applied to medical imaging.
It is intended for routine clinical practices of hospitals treating cancer patients as well as for pharmaceutical companies and CROs in the framework of phase I, II and II clinical trails to evaluate anti-cancer therapies.
Automated retrieval of prior exams, dedicated clinical workflow obeying RECIST rules, automatic 3D registrations of examinations in elastic mode, automated production of reports and graphs.
It is used to follow the course of a patient’s cancer by comparing the latest examination to prior results. This follow-up involves key steps managed by the software that considerably simplifies the radiologist’s work.
First rate partners
The best specialised cancer teams contributed to the development of this module. They are:
- Curie Institute (Paris, France)
- Pitie-Salpetriere (AP-HP–Paris Public Hospitals Authority) (Paris, France)
- Hopital Europeen Georges Pompidou (AP-HP–Paris Public Hospitals Authority) (Paris, France)
- Civil Hospices of Lyon (HCL) (Lyons, France)
- Montpellier University Hospital (Montpellier, France)
Jigesh B Modi